The Drug Approval Debate
Economist Jacob Stegenga challenges the argument that people are dying due to slow drug approval processes. He argues that the existence of a pipeline of life-saving drugs waiting for approval is a misconception. Stegenga also discusses the trade-off between regulatory standards and the potential harm caused by drugs that make it to the market. The conversation sheds light on the complexities of drug regulation and the role of patient advocacy in the process.In this clip
From this podcast
EconTalk
Jacob Stegenga on Medical Nihilism
Related Questions